Vancouver:
SaNOtize Research and Development Corporation (“SaNOtize” or “the Company”) today announced that Enovid, SaNOtize’s Nitric Oxide Nasal Spray (NONS) that protects from viruses and was shown to reduce SARS-CoV-2 viral load in a Phase II trial, is now available in pharmacies throughout Israel.
Enovid was granted an emergency use authorization as a medical device by Israel’s Ministry of Health earlier this year. Enovid provides a physical and chemical barrier to protect from viruses. Enovid releases a small dose of nitric oxide (NO), a natural nano molecule with proven anti-microbial properties including against SARS-CoV-2, the virus that causes COVID-19.
“We are thrilled to have Enovid available in pharmacies in Israel and we are moving as quickly and diligently as possible through regulatory approval processes elsewhere in the world to make NONS available to the wider public,” said Dr. Chris Miller, SaNOtize Co-founder, and Chief Science Officer. “NONS was shown to reduce viral load, which decreases a person’s viral transmission, regardless of variant.”
SaNOtize is also pleased to announce the appointments of Dan Suesskind and Elaine Campbell to its Board of Directors.
Mr. Suesskind served as Chief Financial Officer at Teva Pharmaceutical Industries Ltd. – the world’s largest generic drugmaker – from 1977 until 2008 and was a member of Teva’s board from 2010 to 2014.
Ms. Campbell was President of AstraZeneca Canada Inc. and previously served as Senior Vice-President with DuPont Pharma in the U.S. and Canada. Ms. Campbell is a member of the Advisory Board for Chemical Engineering at the University of Toronto and a member of the MaRS Discovery District Board.
“As SaNOtize begins the next phase in its evolution, we are fortunate to welcome such experienced and respected leaders in the global pharmaceutical industry to our board,” said Dr. Gilly Regev, SaNOtize Co-founder, and CEO. “Their expertise in expanding multinational pharmaceutical organizations will be invaluable.”
On June 23, 2021, SaNOtize announced that it received approval from Health Canada to proceed with the enrollment of volunteers in Phase III trials and that it has submitted an application for a New Drug Submission under Health Canada’s Interim Order. Concurrently, the Company is in the process of regulatory submissions in several other countries, including India, Brazil, and Mexico. These submissions follow the results of a successful Phase IIb clinical trial by SaNOtize, that were accepted for publication by the Journal of Infection.
